TP53 and neoplasm: We reviewed laboratory and clinical evidence to ask whether three features—TP53 status, the total number of DNA changes in the tumor (tumor mutational burden), and the surrounding tumor ecosystem (tumor microenvironment)—can guide more innovative use of immunotherapy.